Researchers in Denmark say they have pinpointed a specific gut mechanism in early infancy that sharply lowers the risk of allergies later on, shedding light on why some children stay symptom‑free while others develop eczema, asthma or food reactions.
How a baby’s gut shapes future allergies
Allergies now affect roughly one in three children in many Western countries, according to French health agency Inserm. Eczema, hay fever and childhood asthma have become routine topics in paediatric waiting rooms. Yet two babies can grow up in the same city, breathe the same air, attend the same nursery — and still have completely different allergy outcomes.
A team from the Technical University of Denmark (DTU) and partner hospitals has focused on what happens in the intestine during the first months of life. Their work, published in Nature Microbiology, tracked babies from birth to age five and found that a particular group of gut bacteria, and the substances they produce, seem to act like a natural brake on allergic responses.
In infants with the right gut bacteria, allergy‑driving immune signals were dialled down by around 60%, without weakening general defences.
That detail matters: a child still needs to fight infections. The Danish results suggest the immune system can be tuned away from allergy without being switched off.
The key player: bifidobacteria and a tiny molecule
The stars of the study are bacteria known as bifidobacteria, common residents of the infant gut. Not all bifidobacteria are equal, though. The team zeroed in on strains that produce a compound called 4‑hydroxy‑phenyllactic acid, often shortened to 4‑OH‑PLA.
4‑OH‑PLA is a metabolite — a small molecule created when bacteria process nutrients. In lab tests using immune cells from children, natural levels of 4‑OH‑PLA cut the production of IgE antibodies by around 60%. IgE is the antibody strongly linked to allergic reactions, from mild hives to severe anaphylaxis.
The presence of 4‑OH‑PLA lowered allergy‑related IgE, while leaving other protective antibodies largely untouched.
This selective effect is what excites immunologists. It hints at a built‑in, microbiome‑driven mechanism that stops the body from overreacting to harmless substances such as pollen, dust mites or peanut proteins.
➡️ When were boats invented? | Live Science
➡️ The day I built a self-watering system from trash I never thought I’d keep
➡️ The streak-free window-cleaning method that still works flawlessly even in freezing temperatures
➡️ The Colorado River’s largest tributary flows ‘uphill’ for over 100 miles — and geologists may finally have an explanation for it
➡️ The quick and effective method to restore your TV screen to like-new condition
➡️ A new map beneath Antarctica’s ice reveals twice as many hills… and a giant valley
➡️ This invisible change in rain is sharply raising the risk of floods
➡️ Get ready: in 2026, generative AI shifts into high gear
Following 147 children from birth
To back up lab findings with real‑world data, the team followed 147 Danish children from birth to five years of age. Regular stool samples were analysed to map their microbiome and its metabolites. Blood tests tracked immune markers and signs of allergic sensitisation, such as rising IgE against common allergens.
Children who had high levels of specific bifidobacteria in the first months of life were much less likely to show allergic sensitisation later on. Genetic analysis of the stool samples showed that these bacteria carried genes needed to produce 4‑OH‑PLA and related compounds.
As allergy tests accumulated over the years — skin prick tests, specific IgE measurements and clinical assessments — a clear pattern emerged: infants with an early, stable population of these aromatic‑lactate‑producing bifidobacteria had a lower risk of developing allergy markers by preschool age.
Why some babies get the “good” bacteria and others do not
Having identified the helpful bacteria, the researchers examined what favours their early colonisation in the gut. Several everyday factors stood out.
- Vaginal birth, rather than caesarean section
- Exclusive breastfeeding during the first weeks or months
- Frequent early contact with other children, such as siblings or daycare peers
Babies born vaginally are exposed to their mother’s vaginal and intestinal microbes during labour. This contact seems to deliver a starter kit of beneficial bifidobacteria. The study reports that babies born by vaginal delivery were up to fourteen times more likely to acquire these strains from their mothers.
Vaginal birth and breast milk together create a microbiological handover that appears to shield some children from future allergies.
Breast milk then feeds these bacteria with specific sugars — human milk oligosaccharides — that they are particularly good at digesting. Early play and contact with other children likely bring in additional microbial diversity, reinforcing this protective community in the gut.
Why Western lifestyles may be eroding this protection
In many Western societies, C‑sections, shorter breastfeeding periods and highly sanitized environments have become increasingly common. The Danish team notes that the exact bifidobacteria strains they identified are now less frequent in infants living in industrialised settings than in previous generations.
That shift may partly explain why allergies have surged over recent decades. The hygiene hypothesis, proposed years ago, argued that children need microbial exposure to train their immune systems. This new work goes further by pointing to a specific group of microbes and a defined molecule that influence allergy risk.
Towards new ways to prevent allergies from birth
If certain bifidobacteria and their metabolites are protective, could they be used as a targeted intervention for high‑risk babies? The Danish team thinks so, and early steps are already under way.
The researchers are testing whether adding 4‑OH‑PLA‑producing bifidobacteria, or the metabolite itself, to infant products can tilt the immune system away from allergy. This might take the form of:
- Probiotic drops for newborns identified as high risk
- Infant formula enriched with selected bifidobacteria strains
- Supplement protocols given during the final weeks of pregnancy and early breastfeeding
Clinical trials in Denmark, including one called the BEGIN study, are assessing whether such approaches can reduce rates of wheeze, eczema and sensitisation to common allergens by school age. Results will take time, since researchers must wait years to see who actually develops asthma or food allergies.
If the strategy works, allergy prevention could shift from childhood management to interventions during the very first months of life.
What this could mean for parents in future
For now, parents should not rush to buy unproven probiotics. Most commercial products do not contain the specific strains highlighted in the study, and the wrong mix might not help — or could simply be useless and expensive.
Instead, paediatricians and researchers expect a more tailored generation of microbiome‑based products, tested in proper trials. In a few years, maternity wards could routinely assess allergy risk — based on family history, birth method and early stool analysis — and offer targeted probiotic regimens where benefits are supported by evidence.
| Early factor | Likely impact on allergy risk (based on current data) |
|---|---|
| Vaginal birth | Higher chance of protective bifidobacteria, lower allergy risk |
| Caesarean section | Lower initial bifidobacteria levels, possibly higher allergy risk |
| Exclusive breastfeeding (first months) | Supports growth of beneficial bifidobacteria |
| Limited microbial exposure | May reduce microbiome diversity and resilience |
Making sense of the science: a quick guide for non‑specialists
Three technical terms recur in this kind of research: microbiome, metabolites and IgE. Understanding them helps unpack the headlines.
- Microbiome: the full collection of bacteria, fungi and other microbes that live on and inside us, especially in the gut.
- Metabolites: the small molecules produced when these microbes break down food or each other’s waste; some act as signals to our immune cells.
- IgE: a class of antibodies that bind to allergens; when IgE levels against, say, pollen are high, exposure can trigger sneezing, itching or asthma attacks.
In the Danish study, bifidobacteria are part of the microbiome; 4‑OH‑PLA is a metabolite; and the change in IgE levels is the measurable immune effect. Put simply: friendly bacteria make a tiny chemical that tells the immune system to calm down around harmless substances.
What might this look like in a real‑life scenario?
Imagine two newborns, both with a family history of asthma. One is born vaginally, breastfed and attends a small daycare from six months. The other is born by C‑section, receives mixed feeding and spends the first year mostly indoors with limited contact outside the household.
In the first child, early stool samples might show abundant 4‑OH‑PLA‑producing bifidobacteria. IgE levels to common allergens stay low, and by age five, skin tests are negative. The second child might show lower levels of these bacteria, higher IgE against dust mites or food proteins, and mild eczema patches appearing in toddlerhood.
This kind of trajectory is what the Danish data hint at. Of course, individual outcomes vary, and no single factor guarantees protection. Genetics, pollution, diet after infancy and viral infections all influence allergy risk. Yet tweaking the microbial starting point may give some children a better chance of staying symptom‑free.
For families and clinicians, the main message is that early life is a window of immune training, not just a waiting room before “real” health questions appear. What happens in the gut during those first months may quietly shape who ends up needing an inhaler, an epinephrine pen or regular antihistamines years later.